Clinical trials: Clinical Trial, Phase I
Advanced Solid Tumors
A Phase I/IIa Study of SYS6041 in Patients With Advanced Solid Tumors
This trial is the first-in-human study of SYS6041, a multicenter, open-label, dose-escalation, dose-reassignment and cohort-expansion Phase I/IIa clinical study, which aims to evaluate the safety, tolerability, pharmacokinetic…
- Trial name
- NCT07744763
- Testing
- SYS6041
- Where
- China
- Volunteers
- 260 people
- Sponsor
- CSPC Megalith Biopharmaceutical Co.,Ltd.
Mucopolysaccharidosis IIIB
A Phase I/II Trial of JR-446 in Mucopolysaccharidosis Type IIIB (MPS IIIB)
This is a global, open-label, Phase I/II, interventional trial in participants younger than 6 years of age with Mucopolysaccharidosis Type IIIB (MPS IIIB), designed to assess the safety and tolerability of JR-446, determine its…
- Trial name
- NCT07640984
- Testing
- JR-446
- Where
- 5 sites in United States, Germany and 1 more
- Volunteers
- 12 people
- Sponsor
- JCR Pharmaceuticals Co., Ltd.
Crohn's Diseases, Crohn's Disease
A Phase 1 Study of ATORM-C in Patients With Crohn's Disease
This Phase 1 study evaluates the safety and tolerability of ATORM-C in patients with Crohn's disease. ATORM-C is an investigational product consisting of autologous adult stem cell-derived intestinal organoids.
- Trial name
- NCT07822087
- Testing
- Autologous Adult Stem Cell-Derived Intestinal Organoid
- Where
- South Korea
- Volunteers
- 18 people
- Sponsor
- ORGANOIDSCIENCES LTD.
Myelodysplastic Syndrome, Acute Myeloid Leukemia
Phase II Part 2 Expansion of Oral Rigosertib in Combination With Azacitidine
This study, is a Phase I/II clinical trial in three parts: Phase I Dose Escalation, Phase II, Part 1 RPTD Cohort, and Phase II, Part 2 Expansion. The first two parts have been completed.
- Conditions
- Myelodysplastic Syndrome, Acute Myeloid Leukemia, Chronic Myelomonocytic Leukemia
- Trial name
- NCT01926587
- Testing
- oral rigosertib, Azacitidine
- Where
- 13 sites in United States, France
- Volunteers
- 45 people
- Sponsor
- Traws Pharma, Inc.
Bone Marrow Disease
A Clinical Trial of CK0801 (a New Drug) in Patients With Bone Marrow Failure Syndrome (BMF)
The goal of this clinical research study is to determine whether it is safe and practical to give CK0801 (a Cord blood-derived T-regulatory cell product) to patients with bone marrow failure syndrome.
- Trial name
- NCT03773393
- Testing
- CK0801
- Where
- 2 sites in United States
- Volunteers
- 18 people
- Sponsor
- Cellenkos, Inc.
Advanced Solid Tumors (Phase 1)
A Phase I Study OfLNF2007 Monotherapy in Patients with Advanced Solid Tumors
A non-randomized, open-ended, phase I dose-escalation and dose-expansion study was designed to evaluate the safety, tolerability, antitumor efficacy, PK and immunogenic characteristics of LNF2007 in patients with advanced solid…
- Trial name
- NCT06752447
- Testing
- LNF2007
- Volunteers
- 94 people
- Sponsor
- Shandong New Time Pharmaceutical Co., LTD
Herpes Zoster
A Safety and Immunogenicity Trial of the Recombinant Zoster Vaccine （CHO Cell）, LYB004 in Adults Aged 50 to 70 Years
This phase 1 study in Australia will evaluate the safety and immunogenicity of the Recombinant Zoster Vaccine (CHO Cell), LYB004 in Adults Aged 50 to 70 Years.
- Trial name
- NCT06335849
- Testing
- LYB004 25µg, LYB004 50µg, SHINGRIX
- Where
- Australia
- Volunteers
- 48 people, healthy volunteers welcome
- Sponsor
- Guangzhou Patronus Biotech Co., Ltd.
Melanoma, Prostate Cancer
A Phase 1 Study of Pegilodecakin (LY3500518) in Participants With Advanced Solid Tumors
This is a first-in-human, open-label, dose escalation study to evaluate the safety and tolerability of pegilodecakin in participants with advanced solid tumors, dosed daily subcutaneously as a monotherapy or in combination with…
- Conditions
- Melanoma, Prostate Cancer, Ovarian Cancer, Renal Cell Carcinoma
- Trial name
- IVY (NCT02009449)
- Testing
- Pegilodecakin, Paclitaxel or Docetaxel and Carboplatin or Cisplatin, FOLFOX (Oxaliplatin/Leucovorin/5-Fluorouracil)
- Where
- 10 sites in United States
- Volunteers
- 353 people
- Sponsor
- Eli Lilly and Company
Solid Tumors
A Study to Evaluate the Safety, Tolerability, PK and Efficacy of Hemay5087 in Patients With Advanced Solid Tumors
An open-label phase I clinical study,which enrolled subjects with advanced solid tumors who have failed to respond to adequate standard therapies or have no available effective standard therapy.
- Trial name
- NCT07624864
- Testing
- Hemay5087
- Volunteers
- 24 people
- Sponsor
- Ganzhou Hemay Pharmaceutical Co., Ltd
Healthy Subjects
A Pharmacokinetic Study of DW6012 (FDC of Dapagliflozin and Sitagliptin) in Healthy Adult Volunteers
This study is to compare and evaluate the safety and pharmacokinetic characteristics (PK) after administration of DW6012 and each component in healthy adult volunteers.
- Trial name
- NCT05403281
- Testing
- DW6012
- Where
- South Korea
- Volunteers
- 41 people, healthy volunteers welcome
- Sponsor
- Dong Wha Pharmaceutical Co. Ltd.
Sepsis
Single-dose/Multiple-doses Incremental Intravenous Injection of SY-005 （Recombinant Human Annexin A5）in Healthy Subjects
This is a single-dose/multiple-doses incremental, randomized, double-blind, parallel, placebo-controlled study on safety, tolerance and pharmacokinetics healthy subjects.
- Trial name
- NCT04217629
- Testing
- SY-005
- Where
- China
- Volunteers
- 96 people, healthy volunteers welcome
- Sponsor
- Suzhou Yabao Pharmaceutical R&D Co., Ltd.
Advanced Malignant Tumors
Phase I Study of SHR-2002 + SHR-1316 in Patients With Advanced Malignant Tumors
This is Phase 1 study FIH to check "Dose Escalation, Dose expansion and Indication expansion". This study is AUSTRALIA only study.
- Trial name
- NCT05082545
- Testing
- SHR-2002 and SHR-1316
- Where
- 4 sites in Australia
- Volunteers
- 19 people
- Sponsor
- Atridia Pty Ltd.
Chronic Idiopathic Constipation
This Study Aims to Evaluate the Safety, Tolerability, Pharmacokinetic and Pharmacodynamic Properties and Food Effect of IN-114199 in Healthy Participants
This study aims to evaluate the safety, tolerability, pharmacokinetic and pharmacodynamic properties and food effect of IN-114199 in healthy participants
- Trial name
- NCT06736912
- Where
- South Korea
- Volunteers
- 80 people, healthy volunteers welcome
- Sponsor
- HK inno.N Corporation
Healthy Subjects
Evaluation of Pharmacokinetic and Safety of NVP-2102 and NVP-2102-R in Healthy Subjects
The purpose of this study is to compare the pharmacokinetics and safety of NVP-2102 and NVP-2102-R.
- Trial name
- NCT05023031
- Testing
- NVP-2102, NVP-2102-R
- Where
- South Korea
- Volunteers
- 53 people, healthy volunteers welcome
- Sponsor
- NVP Healthcare
Hepatic Impairment
Study to Evaluate Orelabrutinib Tablets in Subjects With Hepatic Impairment and Healthy Subject
This is an Open-Label, Parallel, Single-dose, Phase I Clinical Study to Evaluate the Pharmacokinetics and Safety of Orelabrutinib Tablets in Subjects with Varying Degrees of Hepatic Impairment
- Trial name
- NCT05684653
- Testing
- Orelabrutinib Tablets
- Where
- 4 sites in China
- Volunteers
- 34 people, healthy volunteers welcome
- Sponsor
- Beijing InnoCare Pharma Tech Co., Ltd.
Skin and Connective Tissue Diseases
A Single-Centre Clinical Trial to Assess Steroid Induced Skin Atrophy on Healthy Skin
The purpose of this study is to assess steroid induced skin atrophy by sonography.
- Trial name
- NCT02355639
- Testing
- Clobetasol propionate 0.05 % ointment, Betamethasone dipropionate 0.064 % ointment, Petrolatum ointment
- Where
- Germany
- Volunteers
- 16 people, healthy volunteers welcome
- Sponsor
- LEO Pharma
Cancer
Safety, Tolerability and Pharmacokinetics of DCBCI0901 in Patients With Advanced Solid Tumor
Investigate the safety and tolerability of multiple DCBCI0901 infusions in patients with advanced solid tumor Pharmacokinetic parameters will be calculated for DCBCI0901, if data permit.
- Trial name
- NCT02151357
- Testing
- DCBCI0901
- Where
- 3 sites in Taiwan
- Volunteers
- 17 people
- Sponsor
- Standard Chem. & Pharm. Co., Ltd.
Non-Hodgkin's Lymphoma, Chronic Lymphocytic Leukemia
A Trial of GS-9219 in Chronic Lymphocytic Leukemia (CLL), Non-Hodgkin's Lymphoma (NHL) or Multiple Myeloma (MM)
Multi-center, open-label, single-dose, dose-escalating Phase I/II study of GS 9219 in adult patients with relapsed or refractory CLL, NHL or MM. Patients will be enrolled into the study in sequential dose cohorts.
- Conditions
- Non-Hodgkin's Lymphoma, Chronic Lymphocytic Leukemia, Multiple Myeloma
- Trial name
- NCT00499239
- Testing
- GS-9219
- Where
- 20 sites in United States, Czechia and 1 more
- Volunteers
- 32 people
- Sponsor
- Gilead Sciences
Hepatitis C
A Study of TMC435 in Combination With Peginterferon Alfa-2A and Ribavirin for Hepatitis C Virus Genotype-1 Infected Patients Who Participated in a Control Group of a TMC435 Study
The purpose of this study is to investigate the efficacy of a treatment with TMC435 in combination with peginterferon alfa-2a and ribavirin in patients who did not clear their hepatitis C infection with peginterferon alfa-2a and…
- Trial name
- NCT01323244
- Testing
- TMC435
- Where
- 72 sites in United States, Argentina and 20 more
- Volunteers
- 142 people
- Sponsor
- Janssen R&D Ireland
COVID-19
A Clinical Trial to Evaluate the Recombinant SARS-CoV-2 Vaccine (CHO Cell) for COVID-19
phase I study will evaluate safety and immunogenicity of a recombinant SARS-CoV-2 vaccine (CHO cell) in Chinese healthy population aged 3 years and older.
- Trial name
- NCT04869592
- Testing
- low-dose Recombinant SARS-CoV-2 Vaccine (CHO cell), high-dose Recombinant SARS-CoV-2 Vaccine (CHO cell)
- Where
- China
- Volunteers
- 3,100 people, healthy volunteers welcome
- Sponsor
- National Vaccine and Serum Institute, China
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.